Molecular features of adenoid cystic carcinoma with an emphasis on micro<scp>RNA</scp>expression

Andreasen, Simon

doi:10.1111/apm.12828

Cited by 10 publications

(10 citation statements)

References 245 publications

(403 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…MicroRNAs (miRNAs) belong to the family of non-coding RNAs and are ~ 22 nucleotides in length [5]. MiRNAs act as effective post-transcriptional mediators of gene expression via inducing targeted mRNAs degradation or translational repression [5]. Dysregulation of miRNAs has been identified in numerous human malignancies, and miRNAs play important roles in regulating human cancer progression and metastasis [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA-140-5p inhibits salivary adenoid cystic carcinoma progression and metastasis via targeting survivin

2019

View full text Add to dashboard Cite

Background Salivary adenoid cystic carcinoma (SACC) is one of the most frequent carcinomas derived from the salivary gland. Growing evidence implied the involvement of microRNAs (miRNAs) in SACC progression and metastasis. This study aimed to determine the regulatory role of miR-140-5p in SACC progression and metastasis and to explore the underlying mechanisms. Materials and methods MiR-140-5p and survivin mRNA expression levels were determined by quantitative real-time PCR; protein levels were evaluated by western blot assay; cell proliferation, growth, invasion, apoptosis and caspase-3 activity were evaluated by respective in vitro functional assays; xenograft nude mice model was used to assess the in vivo tumor growth; a luciferase reporter assay determined the interaction between miR-140-5p and survivin. Results MiR-140-5p overexpression suppressed SACC cell proliferation and invasion, induced cell apoptosis and inhibited in vivo tumor growth of SACC cells. The loss-of-function studies showed that miR-140-5p knockdown enhanced SACC cell proliferation and invasion, inhibited cell apoptosis and led to an accelerated in vivo tumor growth. The bioinformatics prediction and luciferase reporter assay revealed that miR-140-5p directly targeted survivin 3′ untranslated region, and survivin was inversely regulated by miR-140-5p. Knockdown of survivin exerted tumor-suppressive effects on SACC cells, while enforced expression of survivin counteracted the tumor-suppressive actions of miR-140-5p overexpression in SACC cells. Mechanistically, miR-140-5p modulated the protein expression levels of apoptosis- and epithelial-mesenchymal transition-related mediators as well as matrix metallopeptidase-2/-9 via targeting survivin. More importantly, the down-regulation of miR-140-5p and the up-regulation of survivin were detected in the SACC clinical tissues, and miR-140-5 expression was inversely correlated with survivin mRNA expression level in SACC tissues. Conclusion Our data indicated that miR-140-5p suppressed SACC cell proliferation and invasion, induced cell apoptosis via regulating survivin expression. The present study provide evidence that that miR-140-5p could be a promising target for treating SACC, which requires further investigations.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MicroRNA-140-5p inhibits salivary adenoid cystic carcinoma progression and metastasis via targeting survivin

2019

View full text Add to dashboard Cite

show abstract

“…In addition, several studies have reported that other miRNAs also play a role in the diagnosis, progression and prognosis of ACC (146)(147)(148). In bodily fluids, these miRNAs are circulating and their stability can be easily maintained.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

MicroRNA in adenoid cystic carcinoma (Review)

et al. 2022

Int J Oncol

View full text Add to dashboard Cite

Adenoid cystic carcinoma (ACC) usually arises in the salivary glands, and is a rare tumor, accounting for 1% of all head and neck cancer cases. According to estimates, there are 3-4.5 cases of ACC for every one million individuals. Numerous studies have reported the association between ACC and microRNAs (miRNAs/miRs). miRNAs are endogenous, non-coding small RNAs, 19-25 nt in length, that can regulate target gene expression at the post-transcriptional level. The aberrant expression of miRNAs may be associated with the prognosis and treatment of patients, as well as with tumorigenesis and tumor development. miRNAs are becoming reliable biomarkers for disease detection due to their varied characteristics, and miRNA target-based therapies are increasingly being used in clinical practice. The present review provides a brief introduction to ACC and the biogenesis of miRNAs. A summary of the miRNAs that have been validated by in vitro or in vivo studies is then presented, describing their role in ACC. Contents1. Introduction 2. Clinical features 3. Histopathology and diagnostic imaging 4. Treatment 5. Biogenesis of miRNAs 6. miRNAs in ACC 7. Conclusions and future perspectives

show abstract

“…3,5 Clinically, ACC presents as an indolent and slow-growing lesion. 3,[6][7][8] It is locally invasive and can invade peripheral nerves and blood vessels at an early stage. Around 40% of ACC cases have the potential to metastasise to other distant organs.…”

Section: Introductionmentioning

confidence: 99%

“…Around 40% of ACC cases have the potential to metastasise to other distant organs. 3,4,[7][8][9] Its high propensity for perineural invasion affects the trigeminal and facial nerves of the patient. 3 Risk of distant metastasis is influenced by the difficulty of surgical removal at the primary site and stages of the ACC.…”

Section: Introductionmentioning

confidence: 99%

Role of supportive periodontal management in patient with metastatic cancer

Neo

Mohamad

Rath

et al. 2022

Dent. J. (Majalah Kedokt. Gigi)

View full text Add to dashboard Cite

Background: Treatment of head and neck cancers may cause sequelae affecting patients’ quality of life during and after treatment. As a result, periodontal management of a patient with parotid gland adenoid cystic carcinoma, particularly in advanced stage 4, can be challenging for dental practitioners, especially if the patient is on active oral molecular therapy and undergoing long-term radiotherapy and chemotherapy. Purpose: This report was intended to describe the conservative non-surgical management of tooth 27 with poor prognosis owing to grade II mobility in a patient on active Lenvatinib therapy – where the extraction was not advisable to lessen the risk of osteonecrosis. Case: A 52-year-old female patient was referred by an oncologist to our dental clinic for noncarious toothache. Five years ago, the patient was diagnosed with adenoid cystic carcinoma (ACC) and had a treatment history of radiotherapy, chemotherapy and surgical removal of the left parotid gland to manage the malignancy. Oral examination revealed characteristic findings of periodontitis. Case Management: Ultrasonic scaling, antimicrobial mouth rinses and reinforcement in oral hygiene instructions manage the tooth 27 conservatively. Conclusion: A cautious approach by the dental surgeon, together with the multidisciplinary team caring for cancer patients, is fundamental and helps with the palliative periodontal management of this patient to enhance oral health-related quality of life. With a lack of reports on conservative periodontal therapy in ACC patients, this report highlights the combination of smoking cessation, reinforcement of oral hygiene instructions and conservative periodontal treatment.

show abstract

Molecular features of adenoid cystic carcinoma with an emphasis on microRNAexpression

Cited by 10 publications

References 245 publications

MicroRNA-140-5p inhibits salivary adenoid cystic carcinoma progression and metastasis via targeting survivin

MicroRNA-140-5p inhibits salivary adenoid cystic carcinoma progression and metastasis via targeting survivin

MicroRNA in adenoid cystic carcinoma (Review)

Role of supportive periodontal management in patient with metastatic cancer

Contact Info

Product

Resources

About